image
Healthcare - Medical - Devices - NASDAQ - US
$ 11.54
-1.54 %
$ 300 M
Market Cap
-4.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVRX stock under the worst case scenario is HIDDEN Compared to the current market price of 11.5 USD, CVRx, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVRX stock under the base case scenario is HIDDEN Compared to the current market price of 11.5 USD, CVRx, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CVRX stock under the best case scenario is HIDDEN Compared to the current market price of 11.5 USD, CVRx, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CVRX

image
$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
51.3 M REVENUE
30.53%
-59.5 M OPERATING INCOME
-38.02%
-60 M NET INCOME
-45.55%
-39.1 M OPERATING CASH FLOW
-0.32%
-1.36 M INVESTING CASH FLOW
-130.29%
55.9 M FINANCING CASH FLOW
132.95%
15.3 M REVENUE
14.72%
-10.3 M OPERATING INCOME
21.04%
-10.7 M NET INCOME
18.69%
-8.01 M OPERATING CASH FLOW
23.07%
-52 K INVESTING CASH FLOW
-40.54%
13.8 M FINANCING CASH FLOW
-65.59%
Balance Sheet CVRx, Inc.
image
Current Assets 130 M
Cash & Short-Term Investments 106 M
Receivables 9.27 M
Other Current Assets 14.6 M
Non-Current Assets 3.6 M
Long-Term Investments 0
PP&E 3.57 M
Other Non-Current Assets 27 K
79.40 %6.95 %10.95 %Total Assets$133.4m
Current Liabilities 10.8 M
Accounts Payable 2.58 M
Short-Term Debt 0
Other Current Liabilities 8.18 M
Non-Current Liabilities 51.6 M
Long-Term Debt 50.2 M
Other Non-Current Liabilities 1.45 M
4.14 %13.12 %80.42 %Total Liabilities$62.4m
EFFICIENCY
Earnings Waterfall CVRx, Inc.
image
Revenue 51.3 M
Cost Of Revenue 8.33 M
Gross Profit 43 M
Operating Expenses 102 M
Operating Income -59.5 M
Other Expenses 475 K
Net Income -60 M
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)51m(8m)43m(102m)(59m)(475k)(60m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
83.75% GROSS MARGIN
83.75%
-115.98% OPERATING MARGIN
-115.98%
-116.91% NET MARGIN
-116.91%
-84.39% ROE
-84.39%
-44.95% ROA
-44.95%
-48.55% ROIC
-48.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CVRx, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)202020202021202120222022202320232024202420252025
Net Income -60 M
Depreciation & Amortization 619 K
Capital Expenditures -1.36 M
Stock-Based Compensation 19 M
Change in Working Capital 949 K
Others 3.3 M
Free Cash Flow -40.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CVRx, Inc.
image
Wall Street analysts predict an average 1-year price target for CVRX of $15.9 , with forecasts ranging from a low of $12 to a high of $23 .
CVRX Lowest Price Target Wall Street Target
12 USD 3.99%
CVRX Average Price Target Wall Street Target
15.9 USD 37.41%
CVRX Highest Price Target Wall Street Target
23 USD 99.31%
Price
Max Price Target
Min Price Target
Average Price Target
242422222020181816161414121210108866May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership CVRx, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
19.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
323 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CVRx Reports Preliminary First Quarter 2025 Financial Results First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 globenewswire.com - 1 week ago
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction globenewswire.com - 2 months ago
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 2 months ago
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2 months ago
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago. zacks.com - 2 months ago
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. globenewswire.com - 2 months ago
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. globenewswire.com - 2 months ago
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. globenewswire.com - 3 months ago
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. globenewswire.com - 4 months ago
CVRx: Impressive Top-Line Growth Seems Priced In CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. seekingalpha.com - 5 months ago
8. Profile Summary

CVRx, Inc. CVRX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 300 M
Dividend Yield 0.00%
Description CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact 9201 West Broadway Avenue, Minneapolis, MN, 55445 https://www.cvrx.com
IPO Date June 30, 2021
Employees 206
Officers Mr. Paul Verrastro Chief Marketing & Strategy Officer Mr. Paul Pignato Vice President of Research, Development and Operations Mr. Robert Allen John Chief Revenue Officer Ms. Tonya A. Austin SPHR Chief Human Resources Officer Dr. Philip B. Adamson M.D., M.Sc. Chief Medical Officer Ms. Jonelle R. Burnham Vice President & General Counsel Mr. Kevin Hykes President, Chief Executive Officer & Director Mr. Jared Oasheim Chief Financial Officer Ms. Bonnie Handke M.B.A., R.N. Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics